Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
18.65
-0.46 (-2.41%)
Jul 9, 2026, 2:00 PM EDT - Market open
Apollomics Employees
Apollomics had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
$631,571
Profits / Employee
-$781,357
Market Cap
40.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 1 | 7.69% |
| Dec 31, 2024 | 13 | -32 | -71.11% |
| Dec 31, 2023 | 45 | 2 | 4.65% |
| Dec 31, 2022 | 43 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| PDS Biotechnology | 21 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| ABVC BioPharma | 19 |
| RenovoRx | 17 |
| Lantern Pharma | 16 |
| Eloxx Pharmaceuticals | 10 |
APLM News
- 14 days ago - Apollomics Inc trading resumes - TheFly
- 14 days ago - Apollomics Inc trading halted, volatility trading pause - TheFly
- 14 days ago - Apollomics receives noncompliance notice from Nasdaq - TheFly
- 14 days ago - Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia - GlobeNewsWire
- 7 weeks ago - Apollomics Registration statement: Registration filing - Filings
- 2 months ago - Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewsWire
- 2 months ago - Apollomics Annual report: Q4 2025 - Filings
- 2 months ago - Apollomics Earnings release: Q4 2025 - Filings